A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Clinical trial NCT06733233 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06733233
Sponsor: Guangzhou Women and Children's Medical Center
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer, Estrogen Receptor-Positive HER2 Low Breast Cancer

Start date: 2025-01-01
Primary completion: 2028-01-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.